Tests apixaban or aspirin after stroke with possible hidden atrial fibrillation

Trial details

Who runs it

Assistance Publique - Hôpitaux de Paris

Trial code

NCT06486792

Record updated

5 June 2026

Original description

Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay. After discharge, these patients are typically monitored for AF using devices like Holter monitors or implantable loop recorders. Treatment options during this period include anticoagulants or aspirin. Anticoagulants are more effective in preventing recurrent strokes if AF is present, offering an 80% risk reduction compared to aspirin's 20%. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6-12 months. Despite the clinical rationale for using anticoagulants during this search period, their benefit-risk ratio compared to aspirin has not been fully evaluated.Read full original descriptionShow less

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay. After discharge, these patients are typically monitored for AF using devices like Holter monitors or implantable loop recorders. Treatment options during this period include anticoagulants or aspirin. Anticoagulants are more effective in preventing recurrent strokes if AF is present, offering an 80% risk reduction compared to aspirin's 20%. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6-12 months. Despite the clinical rationale for using anticoagulants during this search period, their benefit-risk ratio compared to aspirin has not been fully evaluated.

Inclusion: Included patients must fulfill the following 4 criteria:; patient aged ≥65 years with:; recent (<15 days) cerebral infarction; with cerebral ischemia proven on MRI or head-CT; with no known atrial fibrillation before stroke and no atrial fibrillation detected during hospital stay (monitoring or telemetry) and no mural thrombus; but with suspected atrial fibrillation:; multiple territorial (i.e., in the territory of a cerebral artery or one of its branches) cerebral infarctions in several arterial territories involving both hemispheres, or in the same hemisphere, or in both anterior and posterior circulation, symptomatic or not; or a single cerebral infarction and systemic emboli (e.g., renal, splenic, hepatic or mesenteric infarction, peripheral emboli in arm or leg), symptomatic or not; or any ischemic stroke with dilation of atrium (>34 mL/m²) or left atrial spontaneous echocardiographic contrast or LAA velocities < 40 cm/sec or pro BNP > 400 pg/mL or left ventricular ejection fraction (LVEF) < 40% or supraventricular extrasystole ≥ 400/24 h or longest "atrial run" ≥ 20 beats on telemetry; or age ≥80 year-old and a single infarction; and a plan to detect atrial fibrillation with, long term Holter ECG, wearing device or implantable loop recorder; with a Rankin score equal or less than 4; patient has signed an informed consent; Patient is affiliated to a social security.

Exclusion: Clear indication to anticoagulant or antiplatelet therapy; Contra-indication to anticoagulant or antiplatelet therapy; Patients with a known cause of stroke, using ASCOD classification A1, C1, S1, O1, D1; Symptomatic brain hemorrhage (the mere presence of microbleeds on gradient echo imaging is not an exclusion criteria); Uncontrolled hypertension (following the judgment of the investigator); Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits; Participation in another interventional clinical trial; Under contraception in case of childbearing potential; Patient under guardianship or curatorship.

ClinicalTrials.gov NCT06486792